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Abstract: Controlled drug delivery systems and polymeric carriers have undergone significant development in recent years. Polymers 
like polylactides (PLA), polyglycolides (PGA), poly(lactide-co-glycolides) (PLGA), are approved by the World Health Organization 
(WHO) and Food and Drug Administration (FDA) as materials that can be used in medicine and pharmacy. Owing to their biodegradable 
nature, polymer materials, such as copolymer poly(DL-lactide-co-glycolide), are widely used in various medical applications; controlled 
release of delivering drugs, carriers in the tissue engineering, fixation of bone fractures, chirurgical strings, etc. Polymeric particles are 
used for the controlled delivery of several types of medicaments, including anticancer agents, antihypertensive agents, immunomodula-
tory drugs, hormones, vitamins and macromolecules, such as nucleic acid, proteins, peptides, antibodies, etc. Preparation of poly(lactide-
co-glycolide) submicron spheres poses serious challenges. The present review attempts to address some important issues related to mi-
cro/nanoparticle-based delivery systems comprising poly(lactide-co-glycolide), with a special reference to PLGA for the controlled deliv-
ery of vitamins. A range of topics is discussed, including formulation aspects of micro- and nanoparticles, the effects of particle size and 
size distribution, most commonly used incorporation techniques, surface modification with stabilizers, surface funcionalization, and fac-
tors affecting degradation and drug release rate. 
Keywords: poly(lactide-co-glycolide), micro- and nanoparticles, drug delivery, drug release, vitamins delivery. 
1. INTRODUCTION 
Nanotechnology has become a rapidly growing field with po-
tential applications ranging from electronics to cosmetics [1-7]. 
Creating nanomaterials such as nanoparticles, nanorods, nanowires, 
nanotubes and thin films is the key component for a successful 
development of nanotechnology owing to their extraordinary physi-
cal and chemical properties resulting from the nanosize effect [7-9]. 
Fueled by flourishing development in preparation of nanomaterials, 
a number of applications in the biomedical field have been pro-
posed, and some of them, such as DNA sensors, controlled drug 
delivery, tumor therapy etc., are coming close to successful devel-
opment [9].  
Conventional drug delivery implies periodic dosing of a com-
pound, which results in drug levels oscillations around a desired 
steady state level, and between the side effect level and the mini-
mum therapeutic level, within the ideal therapeutic window [10]. 
The most part of the drug content tends to be released rapidly after 
the administration, which may cause a rapid increase of the drug 
concentration in the body. Concentration oscillations of the admin-
istered drug may cause alternating periods of ineffectiveness and 
toxicity [7]. Controlled drug delivery strategies have made a dra-
matic impact on medicine. Controlled drug release can be achieved 
by a combination of carrier materials and active agents [11]. Carrier 
matrices are usually formed from biocompatible materials such as 
solid lipid nanoparticles [12-14], inorganic materials [15, 16] or 
spheres fabricated from biodegradable polymers [17, 18]. In gen-
eral, controlled-release polymer systems deliver drugs in the opti-
mum dosage for long periods. Apart from the maintenance of opti-
mum therapeutic drug concentration in blood or in a cell, the advan-
tages of controlled delivery systems include predictable and repro-
ducible release for extended periods of time, enhancement of activ-
ity duration for short half-life drugs, reduction of side effects, fre-
quent dosing and waste of drug, optimized therapy, and better pa-
tient compliance [19]. 
Polymer micro- and nanospheres can be employed to deliver 
medication in a rate-controlled and sometimes targeted manner. 
Biodegradable polymers can be natural polymers, modified natural  
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because they are always biodegradable [19]. Drug delivery systems 
prepared through the combination of biodegradable and biocom-
patible materials make a major focus area in the engineering of 
medical devices [10]. Micro- and nanospheres fabricated from a 
biodegradable polymer for drug delivery systems have become 
increasingly important owing to the fact that such systems enable 
controlled drug release at desired sites [10].  
While advantages of controlled drug delivery can be significant, 
potential disadvantages cannot be ignored: possible toxicity or non-
biocompatibility of the materials used, undesirable by-products of 
degradation, the fact that surgery may be required to implant or 
remove the system, the possibility of patient discomfort caused by 
the delivery device, and the higher cost of controlled-release sys-
tems compared to traditional pharmaceutical formulations [18].  
A number of polymers have been investigated for formulating 
biodegradable nanoparticles, such as polylactide (PLA), polyca-
prolactone (PCL) and poly(lactide-co-glycolide) (PLGA). These are 
biocompatible and biodegradable polymers which have recently 
been the subject of extensive investigation [19-21]. However, due 
to copolymer crystallization, low biodegradation rate or poor flexi-
bility, the application of polymer nanoparticles is limited. For ex-
ample, in case of homopolymer poly(L-lactide), due to its crystal-
line and low biodegradation rate, drug release from relevant drug 
delivery devices is mainly controlled by drug diffusion similar to 
that in non-degradable drug carriers [22]. Biodegradation of polym-
eric biomaterials involves cleavage of hydrolytically or enzymati-
cally sensitive bonds in a polymer, leading to polymer erosion. 
Depending on the mode of degradation, polymeric biomaterials can 
be further classified into hydrolytically degradable polymers and 
enzymatically degradable polymers. The most part of naturally 
occurring polymers undergo enzymatic degradation [19]. Biodegra-
dation of hydrolysable polymers proceeds in a diffuse manner, with 
amorphous regions degrading prior to the complete split of crystal-
line and cross-linked regions [20]. Factors affecting biodegradation 
of polymers might be: chemical structure, chemical composition, 
distribution of repeat units in multimers, presence of ionic groups, 
presence of unexpected units or chain defects, configuration struc-
ture, molecular weight, molecular weight distribution, morphology 
(amorphous/semicrystalline, microstructures, residual stresses), 
presence of low-molecular-weight compounds, processing condi-
tions, annealing, sterilization process, storage history, shape, site of 
implantation, adsorbed and absorbed compounds (water, lipids, 
ions, etc.), physicochemical factors (ion exchange, ionic strength, 
pH), physical factors (shape and size changes, variations of diffu-
sion coefficients, mechanical stresses, stress-and solvent-induced 
cracking, etc.), mechanism of hydrolysis (enzymes versus water) 
[19, 22].  
The objective of this review is to highlight the current status of 
poly(lactide-co-glycolide) as a drug delivery vehicle. This review 
covers synthesis, the effect of particle size and size distribution, 
commonly used incorporation techniques, surface modification by 
stabilizers, surface funcionalization, and factors affecting degrada-
tion and drug release rate.  
2. POLY(LACTIDE-CO-GLYCOLIDE)  
Structure, properties and applications of nanoparticles are 
strongy affected by the properties of the polymer used in their for-
mulation. For each application and drug, one must evaluate the 
properties of the system (drug and particle) and determine the opti-
mal formulation for a given drug delivery application. Polyesters 
based on polylactide (PLA), polyglycolide (PGA), polycaprolac-
tone (PCL), and their copolymers have been extensively employed 
as systems for drug delivery [23-29]. PLGA (Fig. (1)) and PLA 
have been approved by the FDA for numerous clinical applications, 
such as sutures, bone plates, abdominal mesh, and extended-release 
pharmaceuticals [30-35].  
 
 
 
 
Fig. (1). Chemical structure of PLGA polymer. The "m" component repre-
sents lactic acid and "n" component represents glycolic acid. 
Biomedical uses of PLA have been reported since the 1960s 
[31]. Tissue response to such biodegradable materials is character-
ised by minimal localized inflammation and foreign body reaction 
that lessen with time. No toxic effects have been associated with the 
use of such polymers, biodegraded via a random, non-enzymatic 
process into homopolymers of lactic acid and glycolic acid, known 
products of cellular intermediary metabolism [36-38]. PLGA de-
grades through hydrolysis of its ester linkages in the presence of 
water. It has been shown that the time required for the degradation 
of PLGA is related to the ratio of monomers used in its production: 
the higher the content of glycolide units, the lower the time required 
for degradation. An exception to this rule is copolymer with 50:50 
ratio of monomers, which undergoes faster degradation (about two 
months) in both in vitro and in vivo conditions. [39-41]. Miller et al. 
have shown that PLGA 50:50 is the fastest degrading composition, 
with the degradation rate being decreased when either lactide or 
glycolide content of the copolymer was increased [42]. 
PLGA can be synthesized by a polycondensation reaction, or 
via ring-opening polymerization of cyclic diesters (Fig. (2)) [43-
46]. Ring-opening polymerization is currently the preferred method 
for the synthesis for PLGA and PLA due to shorter reaction times 
and higher monomer conversion rates [44-46].  
 
 
 
 
 
 
 
Fig. (2). Ring-opening polymerization of glycolide to polyglycolide. 
Using the properties of polyglycolide and poly(l-lactide) as a 
starting point, it is possible to copolymerize these two monomers to 
extend the range of homopolymer properties [47-49]. Glycolide 
monomer is synthesized through dimerization of glycolic acid. PGA 
is highly crystalline with a high melting point and a glass-transition 
temperature of 35—40°C [50, 51]. Lactide is a cyclic dimer of lac-
tic acid, which has two optically isomeric forms, d and l [48]. L-
lactide is the naturally occurring isomer, whereas dl-lactide is the 
synthetic blend of d-lactide and l-lactide. The homopolymer of l-
lactide (PLLA) is a semicrystalline polymer, while poly(dl-lactide) 
(DLPLA) is an amorphous polymer due to irregularities in its 
polymer chain structure [52, 53]. The greatest part of PLA types 
used in biological applications exist in the racemes D, L form 
(DLPLA) and are amorphous polymers. DLPLA and PLGA have 
glass transition temperatures above body temperature [44]. 
The selection of reactants and the synthesis conditions deter-
mine the physicochemical properties of the resulting polymers, such 
as hydrophilicity, mechanical strength, glass transition and crystal-
linity [54-56]. The parameters that can be used to describe the final 
polymers include weight or number-average molecular weight, 
polydispersity, the ratio of lactic and glycolic acid monomers, the 
ratio of D- and L-lactic acid monomers, the end-group functional-
ity, the segment length of monomeric repeat units, etc [57-60].  
3. FORMULATION ASPECTS OF MICRO AND NANO PO-
LYMERIC PARTICLES 
Depending on the nature and matrix of the selected material, 
methods for obtaining polymer particles can be generally divided 
into three groups: dispersion of preformed polymers, polymeriza-
tion of monomers, and ionic gelation or coacervation of hydrophilic 
polymers. However, other methods such as supercritical fluid tech-
nology and particle replication in non-wetting templates (PRINT) 
have also been described in the literature [61-63]. Many approaches 
are proposed for the preparation of PLGA particles. The emulsifica-
tion-evaporation method [64-67], spontaneous emulsification-
solvent diffusion method (SESD) [20, 68], nanoprecipitation 
method [69, 70] and spray-drying [71-73] are all widely used in 
preparing PLGA particles of various sizes. Each of these methods 
employs a similar first step, where an aqueous drug solution is 
emulsified in an organic polymer solution to form a water-in-oil 
dispersion (W1/O). If appropriate, the drug may also be dispersed as 
a solid powder in an organic polymer solution, or codissolved in a 
common solvent with the polymer. The solution or dispersion is 
then processed according to one of the aforementioned methods. 
During the nanoparticle formation using emulsification-evaporation 
and SESD approaches, toxic organic solvents such as CH2Cl2 and 
CHCl3 are usually employed [68]. To meet the requirement for the 
clinical use, residual solvents should be completely removed from 
PLGA particles [74].  
In solvent extraction or evaporation method, the polymer is dis-
solved in an organic solvent such as dichloromethane, chloroform 
or ethyl acetate, which is also used as a solvent for the hydrophobic 
drug. The mixed polymer and drug solution is then emulsified in an 
aqueous solution containing a surfactant or emulsifying agent to 
form an oil-in-water (o/w) emulsion. After the formation of a stable 
emulsion, the organic solvent is evaporated either by reducing the 
pressure or by continuous stirring. The particle size is found to be 
influenced by the type and concentration of stabilizer, homogenizer 
speed and the polymer concentration [75]. In order to obtain small 
particle size, high-speed homogenization or centrifugation may be 
employed [76, 77]. By changing parameters like aging time (after 
the non-solvent is added), or time and velocity of centrifugal proc-
essing, it is possible to influence morphology, size and uniformity 
of PLGA particles [77]. For example, PLGA powder obtained by 
physicochemical solvent/non-solvent method with the shortest ag-
ing time with non-solvent, the longest time and highest velocity of 
 
the centrifugal processing has the smallest particles and the highest 
uniformity (Fig. (3)) [77].  
Spontaneous emulsification or the solvent diffusion method is a 
modified version of solvent evaporation method [78]. In this 
method, a water-miscible solvent is used along with a small amount 
of the water-immiscible organic solvent as an oil phase. Due to a 
spontaneous diffusion of solvents, an interfacial turbulence arises 
between the two phases, leading to the formation of small particles. 
As the concentration of water-miscible solvent increases, a decrease 
in the size of particle can be observed. Both solvent evaporation 
and solvent diffusion methods can be used for hydrophobic or hy-
drophilic drugs. In the case of hydrophilic drugs, a multiple w/o/w 
emulsion needs to be formed with the drug dissolved in the internal 
aqueous phase.  
In the coacervation technique the coating precipitates onto a 
droplet of the drug [79]. Coacervation consists of three stages tak-
ing place under a constant agitation: first, a solution must be formed 
with three immiscible phases: the core material (active ingredient), 
the coating material and a solvent; second, the liquid coating is 
deposited around the core material, which is accomplished by mix-
ing the coating phase with the solvent phase (in which the active 
ingredients reside); and third, the coating is rigidized thermally or 
by desolvation [79, 80]. Spray-drying offers an attractive and rela-
tively simple alternative to the previous methods. Here, the antigen 
solution or W1/O emulsion is atomised in a flow of drying air at a 
slightly elevated temperature. The organic solvent is rapidly vapor-
ized leaving behind solid micro and nanoparticles that are separated 
from the drying air in a cyclone and collected in a deposition cham-
ber [81, 82]. 
Park et al. developed methods based on filling micromolds with 
polymer microparticles, as opposed to polymer melts, to produce 
microstructures composed of multiple materials, having complex 
geometries, and made using mild processing conditions [83]. Poly-
mer microparticles of 1 to 30 μm in size were made from PLA, 
PGA and PLGA using spray drying and emulsion techniques either 
with or without encapsulating model drug compounds. These poly-
mer microparticles were filled into micromolds at room temperature 
and melted or bonded together to form microstructures according to 
different protocols [83]. 
Emulsion process produced PLGA spheres of 100-250 ?m [84], 
45 ?m [85], 30 ?m [86] in diameter. Modification of the emulsion 
process led towards obtaining spheres with smaller diameters up to 
10 ?m [87]. PLGA microspheres with encapsulated paclitaxel were 
prepared using spray drying technique. The particles were in the 
size range of 1-8μm, suitable for intraperitoneal and intrapleural 
lymphatic targeting delivery [88]. Further modifications of the 
process with additional evaporation produced spherical particles 
with diameters in submicron scale. The first submicron spherical 
particles obtained were 570-970 nm [89] and 244-260 nm [90] in 
diameter. PLGA particles obtained by physicochemical sol-
vent/non-solvent method were in the size range of 110-170 nm [23]. 
Calcium phosphate was incorporated into the PLGA polymer ma-
trix by emulsion procedure using solvent–non-solvent system [91]. 
The use of calcium phosphates (CP) and CP-based composite bio-
materials in medical treatment is currently an interesting field of 
research aimed at developing different biomaterials for the recon-
struction of human tissue [91-94]. Two kinds of composites were 
prepared: microcomposite, with particles 150–200μm in size, and 
nanocomposite, with particles 40±5nm in size [91].  
Sonochemistry is a widely used method for obtaining nanos-
tructured composite materials due to resulting chemical effects, like 
surface influence of radicals, and physical effects, like intensive 
dispersion, homogenisation and emulsification [92]. Sonochemical 
homogenous precipitation was applied for the preparation of 
PLGA-hydroxyapatite (PLGA/HAp) particles [95]. The morphol-
ogy and spatial arrangement of obtained particles processed at low 
temperature during the synthesis process were determined. The 
most regular morphology was obtained for PLGA/HAp composite 
with 90:10 weight percent ratio fabricated at lower (8°C) bulk tem-
perature. These spherical particles were in the range between 50 
and 300 nm in size and they had highly regular spatial arrangement 
[95]. 
PLGA nanoparticles can also be synthesized by the nanopre-
cipititation method as described by Bilati et al. [69]. It was shown 
that the mean particle size was closely dependent on the type of 
non-solvent selected. When alcohols were used, the final mean size 
increased in the sequence: methanol<ethanol<propanol. The 
nanoparticles obtained ranged from about 85 to 560nm in size [69]. 
With spray-drying applied for the preparation of cationic PLGA 
nanospheres as gene delivery vectors, in order to minimize aggrega-
tion and loss of gene transfection efficiency, the mean particle di-
ameter was 100–250nm [73].  
Jin et al. examined PLGA nanoparticles with encapsulated pa-
clitaxel, etanidazole or paclitaxel+etanidazole prepared by o/w and 
a)  b)  c)  
d)  e)  
Fig. (3). SEM images of PLGA particles with different aging time in the presence of non-solvent, and with different time and velocity of the centrifugal proc-
essing: a) 10 min and 15 min on 1500 rpm (bar 5μm) b) 30min and 30 min on 3000 rpm (bar 1μm) c) 5 min and 60 min on 4000rpm (bar 1μm) d) 5 min and 60 
min on 4000 rpm (bar 0.5μm) e) 5 min and 120 min on 6000 rpm (bar 0.5μm). 
 w/o/w emulsification-solvent evaporation method [96]. The pre-
pared nanoparticles were spherical with size between 80 and 
150nm. The drug encapsulation efficiency was higher for paclitaxel 
and lower for etanidazole. With the emulsion evaporation method 
using sodium dodecyl sulfate as a surfactant, the size of the ob-
tained particles ranged from 40 to 70 nm [67].  
4. THE EFFECT OF PARTICLE SIZE AND SIZE DISTRI-
BUTION 
PLGA particles allow the encapsulation of medicaments within 
the polymer matrix, and the crucial requirements for the controlled 
and balanced release of the medicament in the body are their ideal 
spherical shape and narrow size distribution [97]. The size and 
shape of particles play the key role in their adhesion and interaction 
with the cell. Drug release dynamics (rate and concentration) de-
pend on morphology, particle porosity, etc. Chemical structure, 
molecular weight, composition, as well as the synthesis conditions, 
are parameters which influence the final morphology of the poly-
mer [97, 98]. The direct relation between these parameters and 
morphology is insufficiently examined, thus making it a topic of 
many research studies.  
A possible mechanism enabling the particles to pass through 
gastrointestinal (and other physiological) barriers could be: (1) 
paracellular passage—particles ‘‘kneading’’ between intestinal 
epithelial cells due to their extremely small size (<50 nm); (2) en-
docytotic uptake—particles absorbed by intestinal enterocytes 
through endocytosis (particles size<500 nm); and (3) lymphatic 
uptake—particles adsorbed by M cells of the Peyer’s patches (parti-
cle size <5 μm) [99]. 
Jani et al. [100, 101] observed that particles with mean diame-
ters of 50 and 100 nm showed a higher uptake in the rat intestine 
than larger particles. The uptake of nanoparticles was followed by 
their appearance in the circulatory system and distribution to differ-
ent tissues. After the administration of equal doses, 33% of the 50 
nm and 26% of the 100 nm nanoparticles were detected in the intes-
tinal mucosa and gut-associated lymphoid tissues (GALT). In the 
case of 500 nm nanoparticles, only 10% were localized in intestinal 
tissues. Particles bigger than 1 μm in diameter yielded fairly low 
uptake and were exclusively localized in Peyer's patches. Although 
particles>3 μm were found occasionally in the follicle-associated 
epithelia (FAE), the passage to associated lymphoid tissues could 
not be observed.  
Nanoparticles offer a number of advantages over microparti-
cles. For example, nanoscale particles can travel through the blood 
stream without sedimentation or blockage of the microvasculature. 
Small nanoparticles can circulate through the body and penetrate 
tissues like tumors. In addition, nanoparticles can be taken up by 
cells through natural means, such as endocytosis. Nanoparticles 
have already been used to deliver drugs to target sites for cancer 
therapeutics [102] or deliver imaging agents for cancer diagnostics 
[103]. These vehicles can be engineered to recognize biophysical 
characteristics that are unique to the target cells, minimizing thus 
drug loss and toxicity associated with the delivery to non-desired 
tissues. 
Since the smallest capillaries in the body are 5–6μm in diame-
ter, particles distributed into the bloodstream must be much smaller 
than 5μm and they must not form aggregates. An advantageous 
feature of particles smaller than 220nm is that they could be easily 
sterilized by filtration, since the sizes of bacteria and viruses are 
larger [98].  
It has been reported that the size of PLGA particles ranged 
mainly from 100 to 500 nm, the standard deviation being up to 30% 
or more. The size of PLGA particles has been traditionally meas-
ured using photon correlation spectroscopy (PCS, also called dy-
namic light scattering). However, PCS measurement may not be as 
precise as measurements using transmission electronic microscopy 
(TEM). The latter reflect the exact particle size, whereas PCS 
measures merely the hydrodynamic diameter of PLGA particles. 
For example, Astete et al. reported 38± 0.2 nm and 67 ±0.2 nm 
PLGA particles from PCS, but large distribution (15-40%) was 
observed in TEM images [67]. Thirumala et al. reported 20 ± 0.2 
nm and 157 ±0.9 nm PLGA particles using PCS, but their standard 
deviation was broad (50-70%) in TEM images [70]. Therefore, the 
preparation of uniformly sized PLGA particles is still a challenge. 
However, the use of nanosized particles for inhalation treatment 
has certain disadvantages. Their mass median aerodynamic diame-
ter (MMAD) is not suitable for inhalation since their size is too 
small. It is expected that a large fraction of the inhaled dose will be 
exhaled, i.e. that the dose deposited in the lungs will be very small. 
It is reported that particles having 2–3μm in diameter have the most 
effective properties in terms of the deposition in a deep lung site 
[104, 105]. In order to use nanoparticles for an inhalation treatment, 
nanocomposite particles with 2–3μm in diameter were prepared as a 
blend of nanoparticles and additives. The nanocomposite particles 
are designed to decompose into primary nanoparticles after reach-
ing the deep lung site [106]. 
5. COMMONLY USED INCORPORATION TECHNIQUES 
A drug can be dissolved, adsorbed, entrapped, encapsulated or 
covalently attached to the surface of the particles and, depending on 
the method of preparation, nanoparticles, nanospheres or nanocap-
sules can be obtained [53, 106, 107]. Nanocapsules are vesicular 
systems in which a drug is confined to a cavity surrounded by a 
polymer membrane, while nanospheres are matrix systems in which 
a drug is physically and uniformly dispersed [107]. PLGA particles 
are used for the controlled delivery of several classes of medica-
ments like anticancer agents, antihypertensive agents, vitamins, 
immunomodulatory drugs, hormones and macromolecules like 
nucleic acid, proteins, peptides, antibodies, etc. Ideally, “the suc-
cessful” system for a controlled delivery of medicaments should 
have high encapsulation efficiency, i.e., it should incorporate a 
substantial amount of the medicament.  
In literature, two methods for incorporating medicaments into 
PLGA are described. Drugs may be incorporated either simultane-
ously with the formation of nanoparticles (incorporation method), 
or through an absorption of the drug after the formation of nanopar-
ticles by incubating the carrier with a concentrated drug solution 
(adsorption/absorption technique). Drug loading and entrapment 
efficiency largely depend on the solid-state drug solubility in a 
matrix material or polymer (solid dissolution or dispersion), which 
is related to the polymer composition, molecular weight, drug–
polymer interaction and the presence of end-functional groups (es-
ter or carboxyl) [70, 108, 109]. However, for nanoparticles prepared 
by a double emulsion process, the solid-state solubility of the drug 
in the polymer was not found to affect drug loading. Drug loading 
and encapsulation in the nanoparticles appeared to be governed by 
the partition coefficient of the drug between the organic phase and 
the external aqueous phase employed in nanoparticle preparation 
[110]. 
The way in which a drug is distributed in a medium may also 
influence its release profile [111].  
For the multi-reservoir type microspheres composed of poly(dl-
lactide-co-glycolide) and poly(dl-lactide), the influence of the drug-
holding layer and the non-drug-holding layer on drug release pro-
files was studied by Matsumoto et al. [112]. Microspheres with the 
blend of PLGA and PLA were prepared by the W/O type emulsion-
solvent evaporation technique; cisplatin was used as a model drug. 
The results of the study indicate that drug release from multi-
reservoir type microspheres involves the following process: (a) 
rapid release of the drug near the surface of microspheres, (b) for-
mation of micropores in the non-drug-holding layer by hydration 
and erosion, (c) degradation of the drug-holding layer, and (d) dif-
fusion of the drug through micropores [112]. 
6. SURFACE MODIFICATION BY STABILIZERS 
The aggregation of PLGA particles during the process of parti-
cle formation is a notable problem regardless of the preparation 
method. In order to prevent the aggregation of PLGA particles, 
polymer stabilizers are often used. Furthermore, the size and shape 
of the particles can also be influenced by the stabilizer used. Stabi-
lizers or surfactants are amphiphilic molecules that posses both 
hydrophilic and hydrophobic parts. The hydrophilic moiety is called 
the head and the hydrophobic part the tail (or tails) [113]. The hy-
drophobic part may consist of a single chain or may have up to four 
chains [113]. The head can be a charged or uncharged polar group. 
Depending on the nature of the head groups, stabilizers are classi-
fied into anionic, cationic, non-ionic and zwittterionic (amphoteric) 
[113, 114]. The type of the drug dissolved and the conditions of the 
target site will determine the type of surfactant used to carry the 
medicine.  
The most commonly used stabilizers of polymer particles in-
clude polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), 
Tween 80, Fluonic 127 (poloxamer 407), Fluonic 68 (poloxamer 
188), didodecyl dimethyl ammonium bromide (DMAB), carbopol 
(prop-2-enoic acid), etc. [20, 53, 65, 68-70,115-122]. These stabi-
lizers are deposited on the surface of PLGA particles and can affect 
the zeta potential, particle size and particle surface properties. PVA 
and PVP create negatively charged PLGA particles [122]. They 
induce specific zeta potential, which is the electrical potential that 
exists across the interface of all solids and liquids. The value of zeta 
potential is a very important characteristic of the particle and it has 
a significant influence on its stability. With the creation of the spe-
cific zeta potential, PVA (or PVP) reduces the agglomeration be-
cause the particles of the same charge are not attracted to each other 
[122, 123]. Also, the coating of particles with appropriate bioadhe-
sive materials, such as polyvinyl alcohol, poly(ethylene glycol) 
(PEG), vitamin E TPGS, etc., can greatly improve their adhesion 
and absorption into the intestinal cells as well as the ability to es-
cape from the multi-drug resistance pump proteins [124-127]. 
Protection offered by surfactants is primarily a function of their 
surface activity. Unlike proteins, which reduce antigen loss by 
inhibiting unfolding and aggregation at interfaces, surfactants 
provide additional protection against irreversible aggregation of 
partially denatured antigens [82, 128].  
According to literature data, polyvinyl alcohol (PVA) is a 
widely used stabilizer for the production of PLGA nanoparticles 
[122]. The influence of the concentration of PVA and the polymers 
tested on particle size and zeta potential value was evaluated before 
and after freeze-drying of the prepared particles by Vandervoort et 
al. [129]. Leaving PVA out of the formulation increased the size of 
the particles by over 1 μm [129]. The morphology (size and shape) 
and the uniformity of PLGA particles can be modelled under differ-
ents type of stabilizers. PLGA powder obtained in the experiment in 
which PVP was used as a stabilizer consists of highly uniform 
spherical particles with a low level of agglomeration and the parti-
cle size ranging between 110 to 170 nm, which means that they are 
smaller than those of PLGA spheres obtained in the experiment 
with PVA as a stabilizer (150 to 230nm) [122]. Zeta potential val-
ues were usually slightly negative; the most extreme zeta potential 
values were measured when poloxamer and carbopol were em-
ployed. The use of gelatin type A made it possible to achieve posi-
tive values [129].  
It has been demonstrated that the type and concentration of sta-
bilizer, homogenizer speed and polymer concentration determine 
the size of PLGA nanoparticles. Kwon et al. have shown that the 
application of didodecyl dimethyl ammonium bromide (DMAB) as 
stabilizer yields estrogen containing nanoparticles smaller than 100 
nm [130]. 
However, although polymer stabilizers may prevent aggrega-
tion of nanoparticles, they are difficult to remove even through 
washing. Furthermore, most polymer stabilizers do not have func-
tional groups for further modification, which significantly limits 
their biomedical application. So far, only a few studies demon-
strated successful biomolecule conjugation using stabilizers and this 
process usually requires extended experimental time, e.g, 24 h for 
the reaction [131]. 
Also, the use of surfactants should be limited to the minimum 
level in order to avoid possible toxic and hypersensitivity reactions 
[132]. 
7. SURFACE FUNCIONALIZATION 
Great efforts have recently been made to make biomaterials 
more biocompatible. Generally, our living system recognizes bio-
materials as foreign bodies through the surface contact. Therefore, a 
biomaterial that has a surface quite different (different surface 
properties such as crystallinity, topography, texture, defects, el. 
charges, etc.) from that of the living structures may be very poor in 
interfacial biocompatibility [133]. Thus, the rationale for the sur-
face modification of biomaterials is straightforward: retain the key 
physical properties while modifying only the outermost surface to 
influence biointeraction [134, 135]. Nonspecific adsorption of 
plasma proteins on PLGA micro- and nanospheres is a great limita-
tion of drug targeting. Also, a serious handicap in drug targeting is 
the rapid uptake of intravenously injected particulate drug carriers 
by the cells of the reticuloendothelial system (RES), comprising 
mainly the Kupffer cells of the liver and the macrophages of the 
spleen and bone marrow [136]. The circulation time of PLGA mi-
crospheres in a bloodstream in vivo is determined by the physico-
chemical characteristics of the particles, especially their size, sur-
face charge and surface affinity [137]. It has long been known that 
the removal of particles by the spleen increases with increasing 
particle size [138, 139]. The adsorption of plasma proteins, on the 
other hand, is regarded as the key factor in explaining the organ 
distribution of microspheres.  
In order to control the targeted drug delivery of intravenously 
delivered nanoparticles, nanoparticle interactions with other cells, 
such as macrophages must be controlled. Various approaches have 
been developed to control these interactions, ranging from changing 
the size of the particle to changing nanoparticle surface properties 
[140, 141]. In order to eliminate nonspecific protein adhesion and 
decrease uptake by macrophages, nanoparticles can be functional-
ized using protein replant materials, such as poly(ethylene glycol) 
(PEG) [140] and polysaccharides [103, 141]. Nonadhesive surface 
coatings increase the circulation time of the nanoparticles [140] and 
reduce toxic effects associated with non-targeted delivery [142, 
143].  
Because of the inert nature of most commercial polymers, they 
must undergo surface functionalization prior to attachment of a 
bioactive compound [144]. The second step is therefore to optimize 
surface functionalization techniques in order to introduce the de-
sired type and quantity of reactive functional groups. The major 
methods of immobilizing a bioactive compound to a polymeric 
surface are adsorption via electrostatic interactions, ligand–receptor 
pairing and covalent attachment. Non-covalent adsorption is some-
times desirable, as in certain drug delivery applications.  
Polymeric nanocarriers such as poly(DL-lactide-co-glycolide) 
have shown promising pharmacokinetics both at the whole-body 
and cellular levels (passive targeting) [2,145-147]. The active drug 
targeting is usually achieved by the chemical attachment onto a 
targeting component that strongly interacts with antigens (or recep-
tors) displayed on the target tissue, leading to the preferential ac-
cumulation of the drug in the targeted organ, tissue, or cells [2].  
Bioactive compounds for surface functionalization of PLGA 
can be enzymes, peptides, polysaccharides, phospholipids analog, 
poly(ethylene glycol) (PEG), etc [124]. Cheng et al. [148] devel-
oped ~250nm nanparticles-aptamer (NP-Apt) bioconjugates using 
poly(D,L-lactide)–block–poly(ethylene glycol) (PLA–b–PEG) co-
polymer and the A10 RNA Apt [149] that can bind the extracellular 
domain of the prostate specific membrane antigen (PSMA), and 
demonstrated their capability for active binding and uptake by the 
targeted cancer cells in vitro [150]. They also developed ~180 nm 
docetaxel-encapsulated nanoparticles-Apt bioconjugates using 
poly(D,L-lactide–co–glycolide)–block–poly(ethylene glycol) 
(PLGA–b–PEG) copolymer that showed remarkable antitumor 
efficacy in vivo after a single intratumoral administration to subcu-
taneous xenograft mouse models of prostate cancer. 
In the active drug targeting, folic acid is often used as a ligand 
to encourage intracellular uptake of drugs [145,151-153]. Folates 
(the anion form) are low molecular weight vitamins required by 
eukaryotic cells, and their conjugates have the ability to deliver a 
variety of drugs or imaging agents to pathological cells without 
causing harm to normal tissues [2]. Folate targeting is an interesting 
approach for cancer therapy because it offers several advantages 
over the use of monoclonal antibodies [154]. More importantly, 
elevated levels of folate receptors are expressed on epithelial tu-
mors of various organs such as colon, lung, prostate, ovaries, 
mammary glands, and brain [155]. Folate is known to be non-
immunogenic, and folate-conjugated drugs and/or nanoparticles are 
rapidly internalized via receptor-mediated endocytosis [145, 156, 
157].  
Wang et al. have reported silk fibroin coating on PLGA and 
alginate microspheres [158]. Silk coating on the PLGA microsphere 
surface was heterogeneous with an average thickness of about 1 
μm, where as it was homogeneous with a thickness of about 10 μm 
on the alginate microsphere surface. Silk fibroin coatings not only 
stabilized microspheres against degradation but also sustained pro-
tein drug release from the microspheres by providing an effective 
diffusion barrier. Protein drug loading was not changed by silk 
coating in either case. 
PLGA nanoparticles, modified with both alendronate and poly-
ethylene glycol (PEG), were prepared by the dialysis method with-
out additional surfactant in order to evaluate the potency of the 
bone-targeted drug delivery as described by Choi et al [159]. Alen-
dronate, a targeting moiety that has a strong affinity for bone, was 
conjugated to PLGA polymer via carbodiimide chemistry. The 
surface-modified PLGA nanoparticles with various ratios of alen-
dronate and mPEG densities on their surface had a strong and spe-
cific ability to adsorb onto hydroxyapatite. 
Various approaches have been proposed to functionalize the 
surface of biodegradable PLGA microparticles and nanoparticles 
[160-165]. The negatively charged surface of PLGA microparticles 
has been functionalized by electrostatic binding of cationic surfac-
tants, such as cetyltrimethylammonium bromide (CTAB) [166]. An 
alternative to the use of cationic surfactants is electrostatic coating 
with polycationic polymers, such as chitosan, poly(lysine) or 
poly(ethyleneimine) (PEI) [167-169]. 
8. FACTORS AFFECTING DEGRADATION AND DRUG 
RELEASE RATE 
Poly(lactide-co-glycolide) (PLGA) is a highly biocompatible, 
mechanically processable polymer that degrades while yielding 
water soluble, non-toxic products of a normal metabolism [23, 111, 
170-172]. The term "degradation" designates the process of poly-
mer chain cleavage, which leads to the loss of molecular weight. 
Degradation induces subsequent erosion of the material, which is 
defined as the weight loss of the material brought about by the 
polymer chain cleavage [173]. For degradable polymers, two dif-
ferent erosion mechanisms have been proposed: homogeneous or 
bulk erosion, and heterogeneous or surface erosion [174, 175]. 
However, for most polymers, erosion has features of both mecha-
nisms. 
Although PLGA is insoluble in water, it is hydrolytically unsta-
ble and is degraded by hydrolysis of its ester bonds [176]. Through 
this hydrolytic attack, random chain scission occurs, causing it to 
degrade into lactic and glycolic acids [59]. Since PGA is more sus-
ceptible to hydrolysis than PLA, by changing the ratio of these two 
components, PLGA polymers can be synthesized with various deg-
radation rates. Degradation first occurrs in amorphous mi-
cro/nanospheres regions and is followed by a slower degradation in 
crystalline regions. This suggests that crystallinity in polymer 
chains can affect the degradation [111]. 
Various studies have revealed that in vitro and in vivo PLGA 
degradation are the result of several processes occurring simultane-
ously. These include water uptake, swelling, ester hydrolysis, diffu-
sion of oligomers and degradation products, and local pH drop 
[177-182]. PLGA monomers, lactic acid and glycolic acid are non-
toxic and can be removed from the body by normal metabolic 
pathways [180]. However, the biocompatibility of degraded oli-
gomers and particles remains questionable. For example, oligomers 
and polymer particles can elicit inflammatory responses, sometimes 
causing tissue necrosis. This has been documented in several long-
term studies [183, 184]. 
PLGA degrades via backbone hydrolysis (bulk erosion) and the 
degradation products include monomers, lactic acid and glycolic 
acid. It could be expected that the faster degradation of the lower 
molar mass fraction, present in the copolymer, increases the local 
acidity, accelerating thus the hydrolysis of higher molar mass spe-
cies. In other words, when acid accumulation creates a local pH 
drop, catalytic degradation of the polymer itself occurs [23].  
However, until now the degradation process has not been com-
pletely elucidated. From a general point of view, two phenomena 
are discussed. Firstly, degradation causes an increase in the number 
of carboxylic end groups, which are known to autocatalyze ester 
hydrolysis [174, 185]. In the second stage, with increasing the deg-
radation time, the amount of oligomer within the polymer matrix 
increases and soluble oligomers can escape from the whole mass of 
the polymer device. In larger specimens, only soluble oligomers 
located close to the surface can diffuse from the matrix before they 
are totally degraded, whereas oligomers located at more inward 
positions within the matrix remain entrapped and increase the acid-
ity within it. The encapsulated oligomers increase the concentration 
of ester and carboxyl bonds, which results in an increased degrada-
tion rate and autocatalysis in comparison to the outer part of the 
specimen. These diffusion reaction phenomenona [186] lead to a 
differentiation between the surface and the centre in larger speci-
mens [187-189].  
Apart from specimen size [187] and copolymer ratio, it has 
been shown that the degradation rate of PLGA is also affected by a 
number of other factors, such as the type of encapsulated medica-
ment, initial pH, porosity, etc. [23, 190]. 
8.1. Effect of the type of encapsulated medicament  
As for the design of biodegradable polymeric drug carriers, one 
must take into consideration the effect of the drug on the polymer 
degradation and drug release rate [191, 192]. This is especially 
relevant in the case of drug carriers with high drug loadings.  
The physico-chemical properties of the incorporated drug(s) 
might significantly affect the resulting release patterns and degrada-
tion of the polymer matrix, especially at high initial drug loadings. 
For example, high content of freely water-soluble drugs can facili-
tate water penetration and lead to the creation of highly porous 
polymer networks upon drug leaching. In contrast, lipophilic drugs 
can hinder water diffusion into the system, slowing down polymer 
degradation. In the case of significant amounts of acidic and basic 
active agents, additional effects on the PLGA degradation kinetics 
can be expected, because ester hydrolysis is catalyzed by acids and 
bases [193, 194]. 
Frank et al. have studied the effect of the chemical nature of the 
drug on matrix degradation and drug release behavior of degradable 
polymers, using lidocaine as a model drug in base and salt forms 
[194]. It is shown in this study that the drug in the base form has a 
substantial effect on the release characteristics, through an acceler-
ating effect on matrix degradation. Siegal et al. investigated the 
process of degradation and drug release from 50:50 PLGA pellets 
containing 20% (weight) drug, for several common drugs (thiothix-
ene, haloperidol, hydrochlorothiozide, corticosterone, ibuprofen, 
and aspirin) [195]. They found that the mechanism of pellet degra-
dation and the parameters of the drug release rate vary as a function 
of the drug type. The presence of the drug may change the degrada-
tion mechanism from bulk erosion (control) to surface degradation 
(haloperidol), as well as affect the rate of pellet degradation [195]. 
The drug release profile, as defined by the time required for 100% 
release and the steady-state rate, also varies significantly. The drug 
release profile for the four drugs seems to follow the classical diffu-
sion/reaction kinetics. However, efforts to correlate the release rate 
parameters to the drug chemistry (as defined by the density of OH 
groups) or hydrophilicity (as given by solubility in water) did not 
yield a strong relationship. Thus, Siegal et al. have concluded that 
drug incorporation affects the rate of polymer degradation and re-
lease rate significantly, but further studies are needed to determine 
the relationship between the drug properties and the release rate 
[195]. 
8.2. pH Controlled Release  
pH of the release medium was found to be of great importance 
for the resulting release patterns [200]. Drug release from PLGA 
microspheres can range from days to months and, therefore, accel-
erated in vitro drug release testing methods are often used for 
manufacturing batch release [201]. 
Numerous advantages and drawbacks of PLGA and PLGA-
based delivery systems for delivering macromolecular drugs have 
been mentioned in the literature [202]. However, PLGA has a nega-
tive effect on the protein stability during preparation and storage, 
primarily due to the acid-catalyzed nature of its degradation. Its 
hydrolysis leads to accumulation of acidic monomers, lactic and 
glycolic acids within the drug delivery device, thereby resulting in a 
significant reduction of pH of the microenvironment (Fig. (4)) [23] 
and denaturation of the encapsulated proteins [202]. Poor control of 
Table 1. Delivery Systems of PLGA Nano/Microparticles Obtained in Various Labs in 2008 
PLGA Type Drug Method Form/Size Degradation Time References 
50:50 
bone morphogenetic 
protein 
double-emulsion–solvent-
extraction technique 
microspheres at least 42 days in vitro [195] 
85:15 paclitaxel electrospinning technique 
implants in the form of 
microfiber discs and sheets 
over 80 days in vitro with a 
small initial burst 
[196] 
85:15 
vascular endothelial 
growth factor 
a double emulsion/solvent 
extraction technique 
microspheres 
30 
days 
[197] 
75:25 rifampicin using a probe sonicator nanoparticles/nanocomposites / [106] 
50:50; 70:30; 
75:25 
vincristine sulfate and 
quercetin 
modified version of an o/w 
single-emulsion 
solvent evaporation process 
nanoparticles 
70% of drugs released from 
nanoparticles after 24 h 
[198] 
50:50 folic acid 
physicochemical solvent/non-
solvent method 
nanoparticles over 30 days in vitro [144] 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Changes in pH of the phosphate-buffered saline with the immersion time for PLGA particles without and with a different concentration of ascorbic 
acid. 
the pH in PLGA delivery systems has been implicated as one of the 
most significant drawbacks [203].  
Many pH modifiers, mostly basic salts, have been included in 
PLGA formulations in attempt to stabilize the pH, but these tech-
niques may not prevent degradation reactions that are both acid and 
base labile, such as deamidation [204-206]. The inclusion of salts 
with the purpose of modifying pH has also proved to be problem-
atic due to their poor solubility in a great part of organic solvents 
used to dissolve PLGA [206]. The addition of basic salts has been 
linked to an increased water uptake in PLGA matrices [206], which 
may promote hydrolytic peptide and protein degradation reactions. 
Buffers also have the potential to neutralize the acidic monomers 
produced by the PLGA degradation without producing a basic pH. 
8.3. Control of Sphere Porosity 
Another important factor influencing the degradation process of 
poly(DL-lactide-co-glycolide) particles is its porosity. Klose et al. 
reported how porosity and size of the particles affect the drug re-
lease mechanisms from PLGA-based microparticles [207]. Porous 
PLGA particles obtained through the water-in-oil-in-water solvent 
extraction/evaporation method with a medicament incorporated 
were suspended into a phosphate buffer solution pH 7.4 in order to 
monitor the degradation of PLGA and the release of the medica-
ment [207]. In contrast to non-porous microparticles of identical 
composition, the relative drug release rate was found to decrease 
with increasing the drug delivery system size [207]. The size exclu-
sion chromatography (SEC), differential scanning calorimetry 
(DSC) and gravimetric analysis measurements have shown that the 
polymer degradation rate increases with increasing particle size, 
demonstrating that autocatalytic effects play a significant role even 
in small and highly porous PLGA particles [207]. However, this 
effect is considerably less apparent in comparison with non-porous 
devices. It is important to note that this is compensated; the diffu-
sion effect becomes more pronounced with increasing the device 
size. The presence of pores does not only increase the mobility of 
the involved species (drug molecules, acids and bases), but funda-
mentally alters the underlying drug release mechanisms. Generally, 
the release of medicament during the degradation process will be 
faster in case of porous particles. A factor related to the sphere po-
rosity is, also, the initial burst effect, which corresponds to the rapid 
initial release of drug and is normally followed by the relatively 
controlled linear release.  
Sodium chloride, silicone oil, paraffin or pluronic f127 are of-
ten used as porogens [208-214]. For example, Kim et al. have de-
scribed a synthesis of porous PLGA microspheres using the emul-
sion method in which pluronic f127 was used as porogen [215]. 
Human growth hormone (rhGH) was encapsulated in porous PLGA 
microspheres. The protein-loaded porous microspheres were readily 
transformed to non-porous microspheres through a treatment with 
water-miscible solvents under non-aqueous and vapor conditions 
[215]. The resulting non-porous microspheres exhibited sustained 
release profiles over an extended period of time [215]. 
9. PLGA FOR CONTROLLED DELIVERY OF VITAMINS 
Poly(lactide-co-glycolide) is a copolymer material that can also 
be used in creating systems for controlled delivery of vitamins. One 
often hears of a vitamin deficit in human body, and vitamins are 
crucial for its normal metabolic activity. System for the controlled 
delivery PLGA/vitamin can brings to the more balanced and effi-
cient concentration of the vitamin throughout the extended period 
of time. 
For example, ascorbic acid is a water soluble vitamin that can-
not be synthesised and stored in the body. It has a variety of bio-
logical, pharmaceutical and dermatological functions, but it is very 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Comparative results of the stereological examination of PLGA particles and particles with a different ratio of PLGA and ascorbic acid, based on a) 
maximal diameter of the particle Dmax; b) area section Aa and c) perimeter form factor, fL. 
unstable in air, light, heat, moisture, presence of metal ions, oxy-
gen, and base, and it easily decomposes into biologically inactive 
compounds [216]. Ascorbic acid introduced in the body in a greater 
portion gets isolated from the body. However, the encapsulated 
ascorbic acid within the polymeric matrix should have a signifi-
cantly higher efficiency [23, 97]. In order to overcome chemical 
instability of ascorbic acid, a considerable amount of research has 
been staged towards its encapsulation or immobilization [23, 97]. 
Stevanovi? et al. prepared PLGA particles by physicochemical 
solvent/non-solvent chemical methods and centrifugal processing. 
The encapsulation of ascorbic acid in the polymer matrix was per-
formed through a homogenisation of water and organic phases. The 
mean size of nanoparticles containing PLGA/ascorbic acid in the 
ratio 85/15 %, was between 130 and 200 nm (Fig. (5)) [97]. The 
degradation of PLGA with and without ascorbic acid in vitro within 
physiological solution has been tracked for eight weeks and it has 
been determined that PLGA completely degrades within this period, 
releasing the full amount of the encapsulated ascorbic acid [23]. 
Preparation of poly(DL-lactide-co-glycolide) microspheres 
through the solvent evaporation method for the controlled delivery 
of vitamin A palmitate (RAP) is described by Martinez-Sancho et. 
al. [217]. Various quantities of vitamin A (10-80mg) had been in-
corporated into the microspheres, and then their release was 
tracked. The release of vitamin A from the microspheres lasted for 
49 days. The mean size of the microspheres was 21.79μm [217]. 
Recently, Ribeiro et al. described the solvent displacement method 
for the formation of ?-carotene-loaded nanodispersions containing 
PLA and PLGA. ?-carotene is a pigment converted into retinol in 
the body and also possesses provitamin A activity. Due to its anti-
oxidant activity, ?-carotene may play an important role in prevent-
ing degenerative diseases. Nanoparticles containing ?-carotene 
were produced by interfacial deposition of the polymer, due to the 
displacement of acetone from the dispersed phase. Gelatin or 
Tween
®
 20 was used as a stabilizing hydrocolloid in the continuous 
phase. The solvent displacement method shows some advantages, 
such as low energy input, high entrapment efficiency, and high 
reproducibility [218]. 
It is well known that vitamin K5 acts as a coagulant in the liver. 
PLGA is modified with 2-imino-2-methoxyethyl (IME)-thiogal-
actosides (Gal-PLGA) for the controlled delivery of vitamin K5 in 
vivo [219]. Vitamin K5 together with Gal-PLGA was showing co-
agulation activities during the entire measuring period after the 
intravenous application, while free K5 was showing activities up to 
four hours after the administration.  
Feng et al. concluded that vitamin E TPGS (d-?-tocopheryl 
polyethylene glycol 1000 succinate) has great advantages for the 
manufacturing of polymeric PLGA nanoparticles for the controlled 
release of paclitaxel and other anti-cancer drugs. They propose a 
novel formulation for the fabrication of PLGA particles containing 
vitamin E TPGS to replace the current method of clinical admini-
stration and, with further modification, to provide an innovative 
solution for oral chemotherapy. They have found that vitamin E 
TPGS could be a novel surfactant as well as a matrix material when 
blended with other biodegradable polymers. A drug encapsulation 
efficiency as high as 100% can be achieved and the release kinetics 
can be controlled [220, 221]. The size of PLGA particles emulsified 
with vitamin E ranges from 300 to 800nm [222]. 
Vitamin B12 is a water soluble vitamin that can also be incorpo-
rated in the PLGA matrix. Fine particles of vitamin B12 (0.2g) with 
3μm in size and copolymer PLGA of molecular weight 10,000 with 
lactide/glycolide ratio 50/50 (1.8g) were dissolved in methylene 
chloride [223]. This was followed by a sonification in order to ob-
tain homogeneous dispersion, which is used in the latter as an oil 
phase. Polyvinyl alcohol was used as the particle stabilizer. 
Folic acid (folate-the anion form, vitamin B9) is a very impor-
tant vitamin, usually insufficiently introduced into the body. The 
particles of PLGA can be used for the controlled delivery of folic 
acid [224]. The obtaining of PLGA particles for the controlled de-
livery of aspirin and folic acid using the emulsion method (o/w or 
w/o/w) has been described by Kanthamneni et al
1
. Different con-
centrations of folic acid and aspirin (20, 40 or 60%) were added 
into a polymeric solution. The efficiency of the encapsulation was 
between 83 and 91% wt.  
Stevanovi? et al. successfully encapsulated folic acid into 
PLGA particles in various concentrations by physicochemical sol-
vent/non-solvent method, thereby producing particles with different 
morphological characteristics (Fig. (6)) [145]. The particles of 
PLGA/folic acid with a lower content of folic acid had a higher 
                                                
1 Kanthamneni, N.; Prabhu, S. Formulation development of targeted 
nanoparticle-based drug delivery systems for the chemoprevention of colon 
cancer. AAPS Annual Meeting Exposition, 02. November, San Antonio, 
Texas, 2006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). SEM images of particles with a different ratio of PLGA and folic acid a) PLGA; b) PLGA/folic acid 95/5 %; b) PLGA/folic acid 90/10 %; c) 
PLGA/folic acid 85/15 %. 
uniformity, lower levels of agglomeration, smaller size. The 
nanoparticles of PLGA/folic acid 95/5% were spherical in shape 
and their mean size ranged between 140 and 240nm. The percent-
age yields for various PLGA/folic acid ratios were similar, and in 
all cases greater than 50%, whereas the loading efficiency was 
greater than 75%.  
For the folic acid release from degrading PLGA, a number pro-
file has been observed (Fig. (7)) [145]. In the first phase, there is a 
burst effect, caused by the release of the drug adsorbed to the outer 
particle surface. Initially, in the first day of the degradation, 17% of 
folic acid is released. The second phase is marked by a relatively 
slow release due to the diffusion of the drug out of the matrix (from 
the first until the 12
th
 day). The third phase is a phase of an in-
creased drug release, caused by (an extensive) polymer degradation, 
resulting in an increased permeability of the drug in the polymer 
matrix. More than 82% of the encapsulated folic acid was released 
before the end of the experiment.  
The folat has been extensively investigated for its possible us-
age as a ligand for targeted delivery of particles with anticancer 
drugs with the purpose of reducing the drug’s non-specific action 
on healthy cells, but also with the aim to enhance the introduction 
of the drugs into the targeted cells. Such line of research results in 
numerous studies describing the conjugation of PLGA particles 
with folic acid [145, 151, 156, 225]. 
CONCLUDING REMARKS 
This review outlines the research and developmental activities 
related to the application of PLGA and PLGA-based nano/micro-
particles as drug delivery vehicles. The extensive interest in drugs 
encapsulated into PLGA particles brought forth the need to prepare 
such particles in larger quantities, thereby meeting the highest qual-
ity standards, all in order to make them suitable for clinical trials 
and commercialisation. The controlled release of medications from 
PLGA micro and nanospheres is achievable by manipulating the 
physical and chemical properties of the polymer, as well as those of 
the particles. Besides other medicaments, vitamins can also be en-
capsulated into PLGA particles. Owing to their undisputable impor-
tance, they were given a special consideration in this review.  
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